



BioLight Life Sciences Ltd.

(the "Company")

December 11 2024

To: Israel Security Authority
www.isa.gov.il

TASE Tel Aviv Stock Exchange
www.tase.co.il

Re: Interim Results in Human Clinical Study for Novel Retinal Disease Diagnostic Technology

BioLight [TASE:BOLT] is pleased to announce [1] that on December 10, 2024, it received interim results from a clinical feasibility study in humans examining and evaluating a novel technology, to which BioLight was granted an option to license from Harvard University, for diagnosing retinal diseases through tears ("**Clinical Feasibility Study**" and the "**Technology**").

The interim results, derived from 20 tear samples collected from subjects with various retinal diseases or different disease stages (5 samples for each disease or disease stage and 5 control samples from healthy subjects), indicate different biological activity between various disease states. The results are based on preliminary findings regarding different biological activity signatures in a limited number of proteins (identified based on screening approximately ten thousand proteins) and support the continuation of the Clinical Feasibility Study. The continuation of the Clinical Feasibility Study will be aimed at expanding the statistical sample and establishing the interim results.

To the Company's best knowledge, the ability to identify retinal diseases through tear sampling is groundbreaking and highly innovative, with extensive commercial potential.

As of this report, 27 subjects have been recruited for the Clinical Feasibility Study, with approximately 40 subjects expected to participate in total. The study is being conducted at the Tel Aviv Sourasky Medical Center (Ichilov), where tear composition analysis is being performed by Professor Yifat Merbel, currently at the Weizmann Institute of Science, who is one of the Technology's inventors whilst at Harvard University .

The Company estimates that, subject to and in accordance with the recruitment rate, the Clinical Feasibility Study is expected to be completed in the first quarter of 2025.

Forward-looking statement - *the information, details and Company's estimates contained in this report including regarding the potential of the Clinical Feasibility Study and Technology, participant recruitment rate, study results, chances of success, and potential for subsequent collaboration, constitute, are "forward-looking information" as defined in the Securities Law, 1968-5778 which involves high uncertainty, and is based, among other things, on third parties and on many variables over which the Company does not necessarily have control, and therefore it is possible that the information, details and estimates as stated, in practice, will not be realized and/or they will not be realized in full and/or they will be realized in a way that is fundamentally different from what was estimated or expected in the first place.*

[1] This announcement follows the Company's immediate report dated June 2, 2024, regarding the recruitment of the first subject and the immediate report dated May 29, 2023, regarding the Company's signing of a collaboration agreement with AstraZeneca's subsidiary, Alexion AstraZeneca Rare Disease ("Alexion") to conduct the Clinical Feasibility Study (reference numbers: 2024-01-057828 and 2023-01-048874, respectively), which are hereby incorporated by reference.

Free translation: non-binding.

This is a translated version of the Company's immediate report in Hebrew as filed with the Israeli SEC – created for convenience purposes only. In case of contradiction, the Hebrew version will prevail.